Dutasteride
Synonyma: (5alpha, 17beta)-n-{2, 5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-l-ene-17-carboxamide; DUTASTERIDE; (5A, 17)-N-[2, 5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide; Avodart; GI' 198745
CAS: 164656-23-9
MF: C27H30F6N2O2
MW: 528.53
Assay: 99%
Color: cerussa
Dutasteride (tincidunt nomen Avodart) est dual 5-α reductase inhibitor qui conversionem testosteronis vetat ad dihydrotestosterone. (DHT). Usus benignae hyperplasiae prostaticae; sed, periculum praesentationis auget et decrescit libitum.
Dutasteride utilis ad symptomata benignae hyperplasiae prostaticae (BPH); quae in colloquio "dilatatum prostatae". in iis qui regulariter obiexerunt 5-alpha-reductase inhibitoris (finasteride et dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
This class of medications increases rates of erectile dysfunction (with between 5% et 9% developing problems after starting their use). This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that these adverse sexual side effects may persist even after discontinuation of the drug. The FDA has added a warning to dutasteride about an increased risk of high-grade prostate cancer.
While the potential for positive, negative vel neutrae mutationes in potential periculo prostatae developing cancer cum dutasteride non constiterit, argumenta suggessit ut ad tempus incrementum et praevalentiam benigni tumores prostatae minuere possit, sed etiam larva prostatae cancri primo deprehensio.
Regio primaria curationis est aegrotis qui cancer prostatae prostati possunt evolvere dum dutasteride pro benigno hyperplasia prostatica, quae rursus diagnosin et prostatae cancer mature curationem morari potuit, ita potentia augens periculum horum aegris developing summus gradus cancer prostatae.
